Sinopharm Group Co. Ltd.

Sinopharm Group Co. Ltd., a pharmaceutical preparation manufacturer headquartered in China (CN), has disclosed its carbon emissions for several years. In 2024, the company reported total emissions of approximately 544,381,900 kg CO2e. This figure comprises approximately 48,785,710 kg CO2e from Scope 1 emissions, about 177,259,360 kg CO2e from Scope 2 emissions, and approximately 318,336,830 kg CO2e from Scope 3 emissions.

For the preceding year, 2023, Sinopharm Group reported total emissions of approximately 263,415,270 kg CO2e. This included Scope 1 emissions of about 54,715,050 kg CO2e and Scope 2 emissions of approximately 208,700,220 kg CO2e. Scope 3 emissions data was not disclosed for 2023.

Historical data shows Scope 1 and 2 emissions for previous years:

• 2022: Approximately 253,105,280 kg CO2e (Scope 1: about 52,434,340 kg CO2e, Scope 2: approximately 200,670,940 kg CO2e)
• 2021: Approximately 215,691,450 kg CO2e (Scope 1: about 51,430,120 kg CO2e, Scope 2: approximately 164,261,330 kg CO2e)
• 2020: Approximately 208,213,060 kg CO2e (Scope 1: about 52,946,470 kg CO2e, Scope 2: approximately 155,266,590 kg CO2e)
• 2019: Scope 1 emissions were about 37,435,630 kg CO2e and Scope 2 emissions were approximately 105,924,730 kg CO2e.
• 2018: Scope 1 emissions were about 30,741,540 kg CO2e and Scope 2 emissions were approximately 88,611,470 kg CO2e.

It is important to note that for all reported years, Scope 3 emissions data, specifically for purchased goods and services, was listed as missing.

In terms of climate commitments, Sinopharm Group aims to achieve net zero emissions by 2030 for both Scope 1 and Scope 2 emissions, as stated in their 2023 Environmental, Social and Governance Report. This is a near-term target. Additionally, their ultimate parent company, SDIC (State Development & Investment Corporation), aims to achieve net zero emissions by 2050 for Scope 1 and Scope 2 emissions. The emissions data reported for Sinopharm Group is inherited from the parent organisation, Sinopharm Group Co. Ltd., at cascade level 2, where it is identified as a current subsidiary.